HCW Biologicsの空売り状況は、投資家がHCW Biologicsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

HCW Biologics (NASDAQ:HCWB) 株価情報, 空売り情報

HCW Biologics

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

HCW Biologics Inc

RBC Capital analyst Kenneth Lee maintains Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) with a Outperform and raises the price target from $550 to $565.

News

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Ameriprise Finl, Raises Price Target to $565

RBC Capital analyst Kenneth Lee maintains AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>) with a Outperform and lowers the price target from $11 to $10.

AGNC

RBC Capital Maintains Outperform on AGNC Investment, Lowers Price Target to $10

Trading Ideas

Live On CNBC Josh Brown Announces Bought More Chevron

RBC Capital analyst Matthew Swanson maintains Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) with a Sector Perform and lowers the price target from $36 to $32.

XMTR

RBC Capital Maintains Sector Perform on Xometry, Lowers Price Target to $32

RBC Capital analyst Rishi Jaluria reiterates Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) with a Underperform and maintains $40 price target.

Reiteration

PLTR

RBC Capital Reiterates Underperform on Palantir Technologies, Maintains $40 Price Target

Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) and Corpay, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>) disclosed the expansion of their partnership to offer an improved suite of <a href="https://www.benzinga.com/pressreleases/25/04/b45063484/mastercard-and-corpay-launch-strategic-partnership-in-cross-border-payments">corporate cross-border payment solutions</a>. 
As part of the deal, Mastercard will make a $300 million minority investment in Corpay&#8217;s cross-border business, acquiring an approximately 3% equity stake. 
This values Corpay&#8217;s cross-border business at $10.7 billion, or 20 times its forward EBITDA multiple.
Also Read: <a href="https://www.benzinga.com/25/03/44435113/visa-vs-mastercard-the-heavyweight-bout-of-payments">Visa Vs. Mastercard: The Battle For Payment Supremacy Heats Up</a>
The deal will give Mastercard&#8217;s financial institution clients and their customers easier access to comprehensive cross-border payment options, including both card and non-card solutions for transactions of all sizes.
The deal makes Corpay the exclusive provider of large-ticket cross-border payments and currency risk management for Mastercard&#8217;s financial clients.
Additionally, Mastercard Move will reach more small and mid-sized businesses through Corpay&#8217;s network.
Raj Seshadri, chief commercial payments officer at Mastercard, said, &#8220;Our work with Corpay expands our reach into the large and growing cross-border B2B payments space helping our financial institution partners deliver on the non-carded needs of their commercial customers, simply and efficiently.&#8221;
Ron Clarke, Chairman and CEO of Corpay added, &#8220;We expect Mastercard&#8217;s sponsorship of our cross-border solutions will accelerate our financial institution revenue build.&#8221;
In a separate release, Mastercard has launched Mastercard Agent Pay, an innovative program <a href="https://www.benzinga.com/pressreleases/25/04/b45066325/mastercard-unveils-agent-pay-pioneering-agentic-payments-technology-to-power-commerce-in-the-age-o">integrating agentic AI to transform commerce</a>.
Mastercard will collaborate with Microsoft on developing new applications to expand the use of agentic commerce, with plans to include other leading AI platforms in the future. 
Additionally, Mastercard will partner with technology providers like IBM and its watsonx Orchestrate product to accelerate the adoption of B2B agentic commerce use cases.
Jorn Lambert, chief product officer at Mastercard said, &#8220;The launch of Mastercard Agent Pay marks our initial steps in redefining commerce in the AI era, including new merchant interfaces to distinguish trusted agents from bad actors using agentic technology.&#8221;
&#8221;Recognizing the seismic implications of this evolution, we are keen to collaborate with industry players to advance the standards for agentic payments, such as applying the Model Context Protocol to Secure Remote Commerce. This lays the foundation for scale and builds trust in agentic commerce.&#8221;
Mastercard will release its first quarter 2025 <a href="https://www.benzinga.com/earnings">financial results on May 1, 2025</a>.
Investors can gain exposure to the stock via iShares Long-Term U.S. Equity Active ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELT#NASDAQ">BELT</a>) and Direxion Shares ETF Trust Direxion Daily Crypto Industry Bull 2X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMBO#NYSE">LMBO</a>).
Price Action: MA shares are up 0.76% at $538.17 at the last check Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44601859/visa-offers-100-million-to-secure-apple-card-network-in-a-bid-to-outdo-mastercard-report">Visa Offers $100 Million To Secure Apple Card Network In A Bid To Outdo Mastercard: Report</a></li>
</ul>
Photo: rblfmr/Shutterstock

Equities

Large Cap

Movers

BELT

CPAY

LMBO

Mastercard Bets On Cross-Border Payments With $300 Million Corpay Deal

In a world where the vast majority of bond funds are conservative, with treasuries and corporates coming to mind, NYLI MacKay Securitized Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SECR#NYSE">SECR</a>), a structured credit ETF that has $150 million in assets under management, is coloring outside the lines. 
<a href="https://www.benzinga.com/etfs">This ETF</a> provides individual investors a unique window into institutional-quality exposure in residential mortgage-backed securities (RMBS), commercial MBS (CMBS) and asset-backed securities (ABS). And whereas most funds have been fluctuating in the recent market winds, this ETF has not just maintained its balance but danced past the storm, providing robust performance and enticing yield.
We sat down with Zachary Aronson, director and research analyst at MacKay Shields, to take a closer look under the hood. And quite frankly, the engine is anything but standard. The ETF is centered on the knowledge of MacKay Shields, a fixed-income giant with about $140 billion in AUM. The fund was launched in May last year and is managed by a team who lives and works structured credit, and it shows.
Also Read: <a href="https://www.benzinga.com/25/04/45051289/top-3-esg-etfs-to-buy-after-record-global-outflows-long-term-opportunities-amid-the-backlash">Top 3 ESG ETFs To Buy After Record Global Outflows: Long-Term Opportunities Amid The Backlash</a>
&#8220;Securitized products — like MBS, CMBS and ABS — offer compelling yield and diversification characteristics, but they're often underrepresented in traditional bond funds,&#8221; said Aronson. &#8220;With SECR, we saw an opportunity to bring institutional-caliber structured credit exposure to the ETF space in a format that's accessible to a broader range of investors.
&#8220;Many fixed income ETFs are heavily concentrated in Treasuries or corporate credit,&#8221; he added, noting that the rationale behind forming SECR was to design a &#8220;core bond solution with a securitized backbone that historically has had lower correlation to equities and corporates.&#8221;
<h1 class="wp-block-heading">Why Investors Should Consider SECR</h1>
One standout aspect of <a href="https://www.newyorklifeinvestments.com/etf/nyli-mackay-securitized-income-etf-secr/#distributionyields">SECR </a>is active management, a rarity in a market where ETFs often operate on autopilot. And according to Aronson, that's not just a feature — it's the fund's superpower. 
"Structured products are incredibly diverse, with complexity that doesn't lend itself well to a rules-based index. Active management lets us be selective — adjusting exposures across sectors, coupons or deal vintages in real time. During volatility, we're not forced to follow an index down — we can shift into higher-quality tranches, move up in capital structure, or lean into mispriced opportunities. That flexibility has been key in managing risk while seeking to capture upside," he said.
Retail investors tend to avoid structured credit just because it sounds very hard and a bit scary. But SECR was made as straightforward as possible. Shedding light on that, Aronson said, &#8220;We designed SECR to be a single-ticker solution, so investors don't need to pick and choose between MBS, CMBS or ABS themselves. Ultimately, we want investors to understand why the fund is positioned a certain way and how that ties back to macro trends they're already familiar with —like mortgage rates, consumer credit and commercial real estate.&#8221;
And that strategy has been paying off. Amid volatility, SECR hasn't just protected capital, it's generated alpha. Aronson said that leaning into seasoned RMBS securities with compelling yields that are better buffered against an economic recession made that possible. This apart, &#8220;underpriced CMBS bonds with a combination of property types behind them, and a diversified basket of ABS bonds with what we view as strong structural protections&#8221; were also key factors.
Aronson believes that some real estate collateral in CMBS bonds are incorrectly priced and presents good relative value. He also noted the sector is under stress, which is why SECR actively underwrites the credit on all securities. &#8220;We think housing is resilient, especially within seasoned securities where loan-to-value ratios are very low compared to when they were issued,&#8221; he added.
On the ABS side — cars, credit cards, etc. — the team is moving with surgical exactness.
&#8220;The latest trends show a weakening consumer with delinquencies on the higher end, this drives us to be very specific in deal selection where we can target certain collateral types and potential structural protections.  That being said we do not see the consumer being overleveraged to the same extent as the Great Financial Crisis,&#8221; Aronson said.
But discussing triggers and the macro events that can reverse the risk-reward ratio, he said, &#8220;Fed pivot can be the driver of spread compression and price appreciation — but potentially also macro stress rising, particularly in labor markets. If unemployment meaningfully increases, you will see pressure across consumer ABS and housing assets.&#8221; SECR portfolio is constructed for risk management purposes, targeting &#8220;downside protection by structure and seasoning, not only yield,&#8221; Aronson added.
Security selection and knowledge of the subtle risk in different subsectors sets SECR apart from its traditional bond ETF competitors. Aronson said there can be major inconsistencies in risk within the ABS, CMBS and RMBS sectors. Having full access to the securitized market (not just the liquid names), helps SECR seek value where others may not be looking.
Bottom Line
For investors seeking yield with a differentiated risk profile, SECR provides a compelling, actively managed solution amid uncertain fixed-income markets.
&#8220;We consider this is a rare window where securitized credit is offering compelling spread without having to reach far down in quality. We think SECR is a smart way to participate while being thoughtful about risk,&#8221; said Aronson.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/04/45047236/etfs-last-week-funds-lead-the-charge-as-markets-stage-a-return-to-risk-on">ETFs Last Week: Funds Lead The Charge As Markets Stage A Return To Risk-On</a></li>
</ul>
Photo: bigjom jom via Shutterstock

Bonds

Specialty ETFs

Exclusives

ETFs

IQ MacKay Municipal Insured ETF IQ MacKay Securitzed Income ETF

SECR

EXCLUSIVE: Inside The Bond ETF That Thrives In Volatility—MacKay Shields' Zachary Aronson On How SECR Is Quietly Crushing It

American Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFG#NYSE">AFG</a>) has outperformed the market over the past 5 years by 1.31% on an annualized basis producing an average annual return of 15.6%. Currently, American Financial Group has a market capitalization of $10.69 billion. 
Buying $100 In AFG: If an investor had bought $100 of AFG stock 5 years ago, it would be worth $205.21 today based on a price of $127.27 for AFG at the time of writing.
<h3>American Financial Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745945111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In American Financial Group 5 Years Ago Would Be Worth Today

JMP Securities analyst Greg Miller reiterates Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) with a Market Outperform and maintains $165 price target.

TWLO

JMP Securities Reiterates Market Outperform on Twilio, Maintains $165 Price Target

JMP Securities analyst Greg Miller maintains SBA Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) with a Market Outperform and raises the price target from $250 to $270.

SBAC

JMP Securities Maintains Market Outperform on SBA Communications, Raises Price Target to $270

Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported first-quarter 2025 adjusted earnings per share of $2.28, beating the <a href="https://www.benzinga.com/earnings">street view of $2.10</a>.
Quarterly sales of $13.23 billion marginally outpaced the analyst consensus estimate of $13.12 billion.
Quarterly net sales grew 12% (+15% at constant currency), with volume contributing 15 percentage points to growth.
Heart failure drug Entresto <a href="https://www.novartis.com/sites/novartis_com/files/q1-2025-media-release-en.pdf" target="_blank" rel="noreferrer noopener">sales</a> grew 22% at constant currency to $2.26 billion, driven by demand-led growth in China and Japan, with increased penetration in hypertension.
Cosentyx&nbsp;sales jumped 18% at constant currency to $1.53 billion in the quarter. Sales grew mainly in the US, emerging growth markets, and Europe, driven by recent launches and volume growth in core indications.
Sales of the multiple sclerosis drug&nbsp;Kesimpta&nbsp;reached $899 million, up 43% at constant currency. Novartis said sales grew mainly in the US, emerging growth markets, and Europe, driven by recent launches and volume growth in core indications.
Kisqali sales increased 56% cc to $956 million, including +87% growth in the U.S., with strong momentum from the recently launched early breast cancer indication and continued share gains in metastatic breast cancer.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertainties" rel="noreferrer noopener">Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties</a>.
Core operating income was $5.6 billion, up 23% (+27% at constant currency), mainly driven by higher net sales.
Outlook: For fiscal year 2025, Novartis expects Net sales to grow in the high single digits compared to the mid-to-high single digits <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43380284/novartis-q4-earnings-beat-estimates-ceo-dismisses-entresto-patent-expiration-worries" rel="noreferrer noopener">expected earlier</a>.
2025 core operating income is expected to grow in the low double digits, compared to the high single to low double digits forecasted earlier.
"We assume&nbsp;Tasigna,&nbsp;Promacta, and&nbsp;Entresto&nbsp;US generic entry mid-2025 for forecasting purposes," Novartis said in the release.
Reuters cited CEO Vas Narasimhan, who said the company had historically expanded capacity in Europe and other regions to serve the U.S.
&#8220;We now want to ensure that 100% of the demand of our key products in the U.S. is produced in the U.S.,&#8221; Reuters noted, citing Narasimhan in a media call, declining to provide details on volumes.
"Even in this I think complex geopolitical environment, we feel confident we can deliver now this upgraded guidance," Narasimhan <a target="_blank" href="https://www.cnbc.com/2025/04/29/novartis-earning-q1-2025.html" rel="noreferrer noopener">told</a> CNBC's Squawk Box Europe.
Price Action: Novartis stock is up 0.51% at $113.20 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45066980/spotify-grows-subscribers-and-revenue-but-profit-miss-sends-stock-sliding" target="_blank" rel="noreferrer noopener">Spotify Adds 3 Million Subscribers But Profit Miss Sends Stock Sliding</a></li>
</ul>
Image: Shutterstock

Biotech

Earnings

Guidance

Health Care

General

Novartis Q1 Earnings Beat Street View, CEO 'Confident' In Delivering Upgraded Guidance

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has announced the launch of a standalone AI app that will compete with the likes of OpenAI&#8217;s ChatGPT, Google&#8217;s Gemini <a href="https://www.benzinga.com/topic/xai">and xAI&#8217;s Grok</a>. 
What To Know: Meta on Tuesday unveiled the Meta AI app built with Llama 4, designed to give users a more personal AI experience. 
&#8220;People around the world use Meta AI daily across WhatsApp, Instagram, Facebook and Messenger. And now, people can choose to experience a personal AI designed around voice conversations with Meta AI inside a standalone app,&#8221; the company said in a blog <a href="https://about.fb.com/news/2025/04/introducing-meta-ai-app-new-way-access-ai-assistant/">post</a>.
The news comes after CEO Mark Zuckerberg said in January that he believes 2025 will be the year in which a &#8220;highly intelligent and personalized AI assistant&#8221; crosses the 1 billion-user mark, CNBC <a href="https://www.cnbc.com/2025/04/29/meta-launches-standalone-ai-app-to-take-on-chatgpt.html">reported</a>. 
&#8220;I expect Meta AI to be that leading AI assistant,&#8221; Zuckerberg said at the start of the year. 
Meta launched its AI chatbot in 2023 before adding Meta AI search functionality across its family of apps in April. Meta AI had around 700 million monthly active users as of January when Meta last reported quarterly results. 
Meta is set to report results for the first quarter after the market close on Wednesday. The company is expected to report earnings of $5.28 per share and revenue of $41.39 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates. Investors will be watching for signs that the company&#8217;s AI investments are gaining traction after Meta announced plans to spend up to $65 billion building out AI infrastructure this year. 
Meta said on Tuesday that its new AI app is designed to get to know the user, personalizing responses in a natural and seamless way. The new voice conversations feature also helps create a personalized experience by delivering a more natural voice experience trained on conversational dialogue.
&#8220;Meta AI uses Llama 4 to help you solve problems, navigate your daily questions, and better understand the world around you. With the ability to search across the web, it can help you get recommendations, deep dive on a topic, and stay connected with your friends and family. Or if you're just looking to play around with it, we provide conversation starters to inspire your searches,&#8221; the company said. 
META Price Action: <a href="http://benzinga.com/quote/meta">Meta shares</a> were up 0.16% at $550.65 at the time of publication Tuesday. The stock is down about 6% year-to-date, per <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45065712/meta-q1-earnings-on-deck-expert-sees-growth-at-a-reasonable-price">Meta Q1 Earnings On Deck: Expert Sees Growth At A &#8216;Reasonable Price&#8217;</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/algifs">Algi Febri Sugita</a>/Shutterstock.

Tech

Meta Launches AI App To Compete With ChatGPT, Gemini, Grok

Ecolab Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) shares are trading higher after the company reported&nbsp;a first-quarter&nbsp;sales decline of&nbsp;2%&nbsp;year-on-year (Y/Y) to&nbsp;$3.69 billion,&nbsp;missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45064296/ecolab-delivers-continued-double-digit-eps-growth-reported-diluted-eps-1-41-adjusted-diluted-eps-1" rel="noreferrer noopener">consensus estimate of&nbsp;$3.70 billion</a>.
Organic sales grew&nbsp;3% Y/Y, led by growth in the Institutional &amp; Specialty, Pest Elimination, and Life Sciences segments.
Effective the first quarter, Ecolab reorganized its segment reporting: Global Industrial is now Global Water (including the former Water, Food &amp; Beverage, and Paper segments); Global Institutional &amp; Specialty remains unchanged (with Healthcare moving in); Global Life Sciences became a standalone segment; and Global Pest Elimination remains a standalone segment.
In fixed currency, Global Water sales grew&nbsp;3% Y/Y&nbsp;to&nbsp;$1.80 billion, Global Institutional &amp; Specialty fell 3% Y/Y to&nbsp;$1.41 billion, Global Life Sciences upped 5% Y/Y&nbsp;to&nbsp;$167.0 million&nbsp;and, Global Pest Elimination increased&nbsp;7% Y/Y&nbsp;to&nbsp;$278.1 million.
Adjusted operating income increased&nbsp;8%&nbsp;Y/Y to&nbsp;$589.6 million, with an adjusted operating margin of&nbsp;15.9% vs.&nbsp;14.3% a year ago.
Organic operating margin expanded 190 bps Y/Y to 16.0%, on improved value pricing and productivity.
Adjusted EPS of&nbsp;$1.50 (+12%&nbsp;Y/Y)&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">in line with the consensus estimate</a>.
The company held&nbsp;$1.16 billion&nbsp;in cash and equivalents as of March 31, 2025.
Outlook: Ecolab expects&nbsp;second-quarter&nbsp;adjusted EPS of&nbsp;$1.84-$1.94 (+10% to 15% Y/Y), vs. the&nbsp;$1.91 estimate.
The company reiterated 2025 adjusted EPS at $7.42&nbsp;–&nbsp;$7.62 (+12% to 15%),&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">compared to the&nbsp;$7.49&nbsp;estimate</a>.
The company repurchased around 0.6 million shares during the quarter.
Christophe Beck, Ecolab's chairman and chief executive officer, said, &#8221;We expect to deliver continued 12-15% earnings growth this year, even as we face a very unpredictable operating environment with soft end market demand and rapidly changing international trade policy. We are making proactive and strategically consistent adjustments to our delivery path due to these external conditions.&#8221;
&#8221;We look to continue to outperform our end markets as we work to convert our strong new business wins, which all leverage our One Ecolab growth initiative and our record innovation pipeline.&#8221;
&#8221;To overcome the impact from tariffs, we are leveraging the strength of Ecolab&#8217;s world-class supply chain, our ‘local for local&#8217; production model, and our recently announced trade surcharge.&#8221;
Investors can gain exposure to the stock via&nbsp;VanEck Environmental Services ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVX#NYSE">EVX</a>) and&nbsp;iShares U.S. Basic Materials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYM#NYSE">IYM</a>).
Price Action: ECL shares are up 2.3% at $244.51 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/commodities/25/04/44651693/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></li>
</ul>
Photo: Shutterstock

Market Vectors Environmental Services Index Fund

iShares Trust Dow Jones US Basic Materials Sector Index Fund

Ecolab Navigates Soft Demand, Tariffs With Margin Gains, Confirms Full-Year Forecast

JMP Securities analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) with a Market Outperform and maintains $4 price target.

PRLD

JMP Securities Reiterates Market Outperform on Prelude Therapeutics, Maintains $4 Price Target

Live On CNBC Josh Brown Announces Sold Some Pfizer

Late last week, Valero Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) reported <a href="https://www.benzinga.com/news/earnings/25/04/44977776/valero-posts-higher-than-expected-profit-despite-sharp-refining-margin-decline">better-than-declined quarterly profits</a>.
So far this year, the company's stock has underperformed its closest peer, Marathon Petroleum Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) by around 6%. It also underperformed the Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) by about 3%, according to Goldman Sachs.
The Valero Energy Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586f95cd72b34c0001c9b160/neil-mehta">Analyst Neil Mehta</a> upgraded the rating from Sell to Neutral, while raising the price target from $115 to $127.
The Valero Energy Thesis: Many of the headwinds that resulted in the stock's underperformance are now reversing, Mehta said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The analyst stated three reasons for the upgrade:
<ul>
<li>Following consensus revisions, expectations better reflect "the deceleration in refining profitability with VLO 2025 EPS having been negatively revised by ~50% over the last year," he said.</li>
<li>The crude environment seems to be improving and the OPEC had begun adding barrels into the market, Mehta mentioned. "We believe the incremental heavy barrels should support more favorable crude differentials and support margins at Valero," he further wrote.</li>
<li>Although the demand environment in uncertain, the supply side is faced with larger refining closures.</li>
</ul>
"We additionally highlight the company's relatively healthy balance sheet and strong cash flow generation which we believe supports the company's continued commitment to shareholder returns," Mehta said.
Price Action: Shares of Valero Energy had risen by 0.32% to $115.14 at the time of publication on Tuesday.
Read More: 
<ul>
<li><a href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=newssearch&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwj2hvfI_fqMAxXER2wGHWLEOIsQxfQBKAB6BAgJEAE&amp;url=https%3A%2F%2Fwww.benzinga.com%2Fnews%2Fearnings%2F25%2F04%2F44937938%2Fcapital-one-reports-mixed-q1-results-eps-beat-revenue-misses&amp;usg=AOvVaw3g8PTc3dpKR3V3BTnwdyaP&amp;opi=89978449">Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners</a></li>
</ul>
Image: Shutterstock

Analyst Color

Upgrades

Valero Energy Analyst Is No Longer Bearish: Here Are 3 Reasons Why

JMP Securities analyst Patrick Walravens reiterates Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) with a Market Outperform and maintains $270 price target.

PCTY

JMP Securities Reiterates Market Outperform on Paylocity Holding, Maintains $270 Price Target

JMP Securities analyst Reni Benjamin reiterates Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Market Outperform and maintains $28 price target.

KURA

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $28 Price Target

American International Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) has outperformed the market over the past 5 years by 1.63% on an annualized basis producing an average annual return of 15.93%. Currently, American International Gr has a market capitalization of $48.61 billion. 
Buying $1000 In AIG: If an investor had bought $1000 of AIG stock 5 years ago, it would be worth $2,083.69 today based on a price of $81.93 for AIG at the time of writing.
<h3>American International Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745944218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning American International Gr Stock In The Last 5 Years

<a href="https://www.aboutamazon.com/news/retail/amazon-response-to-white-house-tariffs">https://www.aboutamazon.com/news/retail/amazon-response-to-white-house-tariffs</a>

AMZN

"The team that runs our ultra low cost Amazon Haul store considered the idea of listing import charges on certain products. This was never approved and is not going to happen."- Amazon

Press Releases

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

HCW Biologics and WY Biotech Announce License Agreement  for Immunotherapeutic Product Candidate

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

IPOs

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

Comments

HCW Biologics

空売り

HCW Biologics (NASDAQ:HCWB) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル